Status: Recruiting
Baricitinib in the Treatment of Intestinal Behçet's Syndrome
This study aims to conduct a randomized controlled trial to compare the efficacy and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS). The objective is to demonstrate if Baricitinib is non-inferior to ADA in controlling BS inflammation, reducing BS recurrence， alleviating gastrointestinal symptoms and promoting intestinal mucosal healing.
Participants needed: 56
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Peking Union Medical College HospitalUpdated: Sep 21, 2026Locations: 2
Eligibility criteria
Refer to the consensus on the diagnosis and treatment of intestinal Behçet's syn... [+5]
Diagnosis of other diseases such as Crohn's disease, ulcerative colitis, lymphom... [+14]